The Oncology Institute, Inc.(TOI)Earnings, Financials & Key RatiosThe Oncology Institute, Inc. (TOI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to achieve operational break-even, combined with a negative equity position of -$16.3M and persistent cash burn, suggests significant liquidity risks that outweigh the current top-line growth trajectory.
The Oncology Institute, Inc. (TOI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
The Oncology Institute, Inc. (TOI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.02vs $0.07+71.4% | $147Mvs $142M+3.8% |
| Q2 2026 | Mar 12, 2026 | $0.06vs $0.08+25.0% | $142Mvs $140M+1.6% |
| Q4 2025 | Nov 13, 2025 | $0.14vs $0.12-16.7% | $137Mvs $140M-2.3% |
| Q3 2025 | Aug 13, 2025 | $0.14vs $0.14+0.0% | $120Mvs $123M-2.2% |
Recent stock market news and headlines for The Oncology Institute, Inc. (TOI)
One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.
Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.
The Oncology Institute (TOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tom Yeung here with your Sunday Digest . In 2025, two professors wanted to see whether ChatGPT made people less creative.
Key metrics vs top competitors for The Oncology Institute, Inc. (TOI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.80 | $5.9B | -10.74 | 27.79% | -12.06% | — | — | |
| $4.31 | $578.32M | -28.73 | 22.42% | -4.63% | -4.34% | — | |
| $1.07 | $672.52K | -0.23 | -67.7% | -1319.55% | -105.46% | — | |
| $71.80 | $1.09B | 50.56 | 16.33% | 1.52% | 1.36% | — | |
| $21.57 | $3.37B | 16.98 | 13.03% | 3.64% | 15.28% | — | |
| $105.97 | $1.98B | 20.34 | 23.21% | 6.89% | 9.34% | — |
The Oncology Institute, Inc. (TOI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
The Oncology Institute, Inc. (TOI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 13, 2026·SEC
Mar 12, 2026·SEC
Get notified when TOI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
The Oncology Institute, Inc. (TOI) stock FAQ — growth, dividends, profitability & financials explained
The Oncology Institute, Inc. (TOI) reported $545.8M in revenue for fiscal year 2025. This represents a 251% increase from $155.4M in 2019.
The Oncology Institute, Inc. (TOI) grew revenue by 27.8% over the past year. This is strong growth.
The Oncology Institute, Inc. (TOI) reported a net loss of $43.5M for fiscal year 2025.
The Oncology Institute, Inc. (TOI) had negative free cash flow of $25.7M in fiscal year 2025, likely due to heavy capital investments.
